Jane Street’s Briacell Therapeutics BCTX Stock Holding History

Jane Street’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-198	Closed	-$16.8K	–	9422
2024 Q4	$16.8K	Buy	+198	New	+$23.7K	﹤0.01%	9148
2022 Q4	–	Sell	-647	Closed	-$546K	–	9130
2022 Q3	$546K	Buy	647 +312	+93%	+$313K	﹤0.01%	6533
2022 Q2	$290K	Buy	+335	New	+$331K	﹤0.01%	7661
2021 Q4	–	Sell	-235	Closed	-$308K	–	10052
2021 Q3	$285K	Buy	+235	New	+$216K	﹤0.01%	8286

Other funds holding BCTX

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CWP

Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HWA

HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Jane Street's BCTX Position: Q1 2025 in Review

Jane Street sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 198 shares — an estimated $16.8K sold.

Jane Street first reported a position in BCTX in Q3 2021 and held it in 4 quarters. The position peaked at $546K in Q3 2022. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

Jane Street reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
Jane Street sold 198 Briacell Therapeutics shares in Q1 2025, an estimated $16.8K.
Jane Street first reported a position in Briacell Therapeutics in Q3 2021 and held it in 4 quarters.
Jane Street's Briacell Therapeutics position peaked at $546K in Q3 2022.
13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.